Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study

International Journal of Urology

Volumn 13, Issue 10, 2006, Pages 1280-1285

  Maruyama, Osamu ^a   Kawachi, Yoshio ^a   Hanazawa, Kisaburo ^a   Koizumi, Kazuo ^a   Yamashita, Ryo ^a   Sugimura, Sosuke ^a   Honda, Shin Ichi ^b   Sugiyama, Yoshiki ^c   Saitoh, Toshihiko ^c   Noto, Kensho ^d  

^a JUNTENDO UNIVERSITY   (Japan)

^b Yatsu Hoken Hospital   (Japan)

^c Chiba Central Medical Center   (Japan)

^d Noto Clinic   (Japan)

Author keywords

Anticholinergic agent; Benign prostatic hyperplasia; Naftopidil; Storage symptom

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; NAFTOPIDIL; OXYBUTYNIN; PROPIVERINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; FLOW RATE; HUMAN; MALE; MONOTHERAPY; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESIDUAL URINE; STOMACH PAIN; STORAGE DISEASE;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; BENZILATES; CHOLINERGIC ANTAGONISTS; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; MALE; MANDELIC ACIDS; NAPHTHALENES; PIPERAZINES; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; TREATMENT OUTCOME; URINARY RETENTION; URODYNAMICS;

EID: 33749000864     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2006.01538.x     Document Type: Article

References (20)

1. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 469-71.
2. Jolleys JV, Donoban JL, Nanchahal K, Peters TJ, Abrams P. Urinary symptoms in the community: how bothersome are they? Br. J. Urol. 1994; 74: 551-5.
3. Sanematsu H, Hirakawa S, Miyagawa I. Oxybutynin hydrochloride and α-adrenergic blockade combination therapy for pollakisuria due to benign prostatic hypertrophy. Nishinihon J. Urol. 1995; 57: 984-5.
4. Saitoh H, Yamada T, Oshima H et al. A comparative study of the efficacy and safety of tamsulosin hydrochloride alone and combination of propiverine hydrochloride and tamsulosin hydrochloride in the benign prostatic hypertrophy with pollakisuria and/or urinary incontinence. Jpn. J. Urol. Surg. 1999; 12: 525-36.
5. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G. Combination treatment with an α-blocker plus an anticholinergic agents for bladder outlet obstruction: a prospective randomized, controlled study. J. Urol. 2003; 169: 2253-6.
6. Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int. 2004; 94: 817-20.
7. Nishino Y, Moriyama Y, Hagiwara N, Miwa Y, Deguchi T. A comparative crossover study for effectiveness of naftopidil and tamsulosin in patients with benign prostatic hyperplasia. Jpn. J. Neurogenic Bladder Soc. 2001; 12: 82.
8. Hayashi T, Sakai Y, Saito K et al. A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia. Hinyokika Kiyo 2002; 48: 7-11.
9. Ikemoto I, Kiyota H, Ohishi Y et al. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two-drug crossover study. Int. J. Urol. 2003; 10: 587-94.
10. Masuda M, Hirokawa M, Furuhata A et al. Etiology of nocturia and clinical efficacy of naftopidil on nocturia in patients with benign prostatic hyperplasia. Hinyokika Kiyo 2004; 50: 309-14.
11. Homma Y, Kawabe K, Tsukamoto T et al. Estimate criteria for efficacy of treatment in benign prostatic hyperplasia. Int. J. Urol. 1996; 3: 267-73.
12. 1-adrenoceptors. Jpn. J. Pharmacol. 1999; 79: 447-54.
13. 1-adrenergic receptor subtypes in human detrusor. J. Urol. 1998; 160: 937-43.
14. 1-adrenergic receptor subtype expression by bladder outlet obstruction. J. Urol. 2002; 167: 1513-21.
15. Sugaya K, Nishijima S, Miyazato M, Ashitomi K, Hatano T, Ogawa Y. Effects of intrathecal injection of tamsulosin and naftopidil, alpha-1A and -1D adrenergic receptor antagonists, on bladder activity in rats. Neurosci. Lett. 2002; 328:74-6.
16. Fredericks CM, Anderson GF, Kreulen DL. A study of the anticholinergic and antispasmodic activity of oxybutynin (dipropan) on rabbit detrusor. Invest. Urol. 1975; 12: 317-19.
17. Riotte J, Mutschler E. [The spasmolytic activity of propiverine and some of its structural analogs.] Arzneimittelforschung 1987; 37: 300-2 (in German).
18. 1d-adrenoceptor J. Urol. 2005; 174: 370-4.
19. Yoshino Y, Oishi Y, Onodera S et al. Clinical study of the relationship between residual urine and urinary tract infection in patients with voiding disorders. Rinsyo Hinyokika 2000; 54: 455-7.
20. Suzu H, Saito Y. Clinical efficacy of propiverine hydrochloride in patients with pollakisuria or urinary incontinence: effect on lower urinary tract function. Nishinihon J. Urol. 1999; 61: 689-95.